Hepatoprotective effects of rubiadin, a major constituent of Rubia cordifolia Linn.

The hepatoprotective effects of rubiadin, a major constituent isolated from Rubia cordifolia Linn., were evaluated against carbon tetrachloride (CCl4)-induced hepatic damage in rats. Rubiadin at a dose of 50, 100 and 200 mg/kg was administered orally once daily for 14 days. The substantially elevated serum enzymatic activities of serum glutamic oxaloacetic transaminase (SGOT), serum glutamate pyruvate transaminase (SGPT), serum alkaline phosphatase (SALP) and gamma-glutamyltransferase (gamma-GT) due to carbon tetrachloride treatment were dose dependently restored towards normalization. Meanwhile, the decreased activities of glutathione S-transferase and glutathione reductase were also restored towards normalization. In addition, rubiadin also significantly prevented the elevation of hepatic malondialdehyde formation and depletion of reduced glutathione content in the liver of CCl4 intoxicated rats in a dose dependent manner. Silymarin used as standard reference also exhibited significant hepatoprotective activity on post treatment against carbon tetrachloride induced hepatotoxicity in rats. The biochemical observations were supplemented with histopathological examination of rat liver sections. The results of this study strongly indicate that rubiadin has a potent hepatoprotective action against carbon tetrachloride induced hepatic damage in rats.

Familial predisposition for degenerative disc disease. A case-control study.

STUDY DESIGN: This case-control study was undertaken to determine if relatives of patients who had been admitted for surgery for degenerative disc disease-related problems were at increased risk for lower back pain or sciatica. OBJECTIVES: To determine if familial factors play a role in placing a person at risk for development of degenerative disc disease of the lumbar spine. SUMMARY OF BACKGROUND DATA: It is known that smoking and various occupational factors can place a person at risk for degenerative disc disease problems. It is not known if a familial predisposition may also exist. METHODS: The family members and relatives of 65 patients who had undergone surgery for lumbar degenerative disc disease were interviewed with a standardized questionnaire and compared with a control group of 67 patients who had been admitted to hospital for non-spine-related orthopedic procedures. The same interview and standardized questionnaire was used for both groups by a single observer. RESULTS: In the study group of 65 patients who had undergone surgery for degenerative disc disease, 44.6% were noted to have a positive family history, whereas 25.4% of the patients in the control group had a positive family history. Eighteen and one-half percent of relatives in the study group had a history of having spinal surgery, compared with only 4.5% of the control group. CONCLUSIONS: The results indicate that a familial predisposition to degenerative disc disease can exist along with other risk factors.

Comparison of long-term patency of "horseshoe" saphenous vein grafts with and without valves.

OBJECTIVE: The paper analyzes the long-term patency of valveless and valvular limbs of reversed saphenous veins. METHODS: Between 1983 and 1988, 335 patients underwent isolated coronary artery bypass grafting (CABG) with 1,329 grafts. Eighty-three patients had follow-up angiography over 8-12 years. The side-to-side saphenous vein to aortic "horseshoe" anastomosis was created just before the first valve from the ankle (naturally a valveless portion). The valveless (ankle end) was depicted in every case. These patients with angiography were similar to 252 patients without angiography in terms of age, gender, number of grafts, diseases vessels, single (A) and sequential (B) grafts and actuarial survival. In the 83 patients, graft patency was 75%. Overall patency was the same in B versus A grafts (76% versus 74.6%); valveless patency (78.7%) was slightly better than valvular patency (73.3%). RESULTS: In patients with B grafts (88.6%) valveless patency was significantly better than valvular patency (71.9%) (P < 0.02). The patency of B-valveless to the left coronary bed was also better, (86.8% versus B-valvular 70.5%, P < 0.04). Attrition of the B-valveless and B-valvular grafts was similar up to 8 years, but by the 12th year it had become significantly different (P < 0.05). The 12-year actuarial survival rate of the patients was 87.7%. CONCLUSIONS: We recommended the use of valveless vein segments when possible.